Submit your email to push it up the queue
GlaxoSmithKline Consumer Healthcare, Inc. (GSK Consumer Healthcare) is a leading player in the global consumer health industry, headquartered in California. Founded in 2019, following the merger of GlaxoSmithKline's consumer health division with Pfizer's consumer healthcare business, the company has rapidly established itself in key operational regions, including North America, Europe, and Asia. GSK Consumer Healthcare focuses on a diverse range of products, including oral health, pain relief, respiratory health, and dietary supplements. Its portfolio features well-known brands such as Sensodyne, Panadol, and Voltaren, which are distinguished by their commitment to scientific innovation and consumer trust. With a strong market position, GSK Consumer Healthcare continues to achieve notable milestones, reinforcing its reputation as a leader in the consumer healthcare sector.
How does GlaxoSmithKline Consumer Healthcare, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
GlaxoSmithKline Consumer Healthcare, Inc.'s score of 100 is higher than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
GlaxoSmithKline Consumer Healthcare, Inc., headquartered in California, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of GSK plc, which means that any climate commitments or emissions data may be inherited from its parent organisation. GSK plc has set ambitious climate targets, which include commitments to reduce greenhouse gas emissions across its operations. These initiatives are part of a broader strategy to achieve net-zero emissions by 2030 for its own operations (Scope 1 and 2) and by 2045 for its value chain (Scope 3). The company is actively engaged in various sustainability initiatives, including participation in the Science Based Targets initiative (SBTi), the Carbon Disclosure Project (CDP), and the RE100 initiative, which focuses on 100% renewable energy. While specific emissions figures for GlaxoSmithKline Consumer Healthcare, Inc. are not available, the overarching climate commitments from GSK plc indicate a strong focus on reducing carbon footprints and enhancing sustainability practices across its corporate family.
Access structured emissions data, company-specific emission factors, and source documents
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 851,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 745,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | 16,093,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | 00,000,000,000 | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
GlaxoSmithKline Consumer Healthcare, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.